A first step against idiopathic pulmonary fibrosis.
作者信息
Crestani B
出版信息
Eur Respir Rev. 2011 Sep 1;20(121):130-1. doi: 10.1183/09059180.00003711.
Abstract
摘要
相似文献
1
A first step against idiopathic pulmonary fibrosis.对抗特发性肺纤维化的第一步。
Eur Respir Rev. 2011 Sep 1;20(121):130-1. doi: 10.1183/09059180.00003711.
2
Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?新兴潜在疗法：特发性肺纤维化患者的新希望？
Eur Respir Rev. 2011 Sep 1;20(121):201-7. doi: 10.1183/09059180.00002011.
3
Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.吡非尼酮：特发性肺纤维化的抗纤维化药物。
Expert Rev Respir Med. 2010 Jun;4(3):301-10. doi: 10.1586/ers.10.32.
4
Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential.特发性肺纤维化的药物治疗：现状与未来潜力。
Eur Respir Rev. 2017 Sep 27;26(145). doi: 10.1183/16000617.0071-2017. Print 2017 Sep 30.
5
Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program.吡非尼酮治疗特发性肺纤维化：CAPACITY 研究。
Expert Rev Respir Med. 2011 Aug;5(4):473-81. doi: 10.1586/ers.11.52.
6
The therapy of idiopathic pulmonary fibrosis: what is next?特发性肺纤维化的治疗：下一步是什么？
Eur Respir Rev. 2019 Sep 4;28(153). doi: 10.1183/16000617.0021-2019. Print 2019 Sep 30.
7
Evolvement of best practice in diagnosis and management of idiopathic pulmonary fibrosis.特发性肺纤维化诊断与管理的最佳实践进展
Eur Respir Rev. 2014 Mar 1;23(131):3-4. doi: 10.1183/09059180.00008713.
8
Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.单中心真实世界经验：吡非尼酮治疗特发性肺纤维化和特发性非特异性间质性肺炎纤维化患者的疗效。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620963015. doi: 10.1177/1753466620963015.
9
What have we learned from basic science studies on idiopathic pulmonary fibrosis?特发性肺纤维化的基础科学研究给我们带来了什么启示？
Eur Respir Rev. 2019 Sep 11;28(153). doi: 10.1183/16000617.0029-2019. Print 2019 Sep 30.
10
Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.特发性肺纤维化患者在接受抗纤维化治疗前后用力肺活量下降的预后意义。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620953783. doi: 10.1177/1753466620953783.
引用本文的文献
1
Role of redoximiRs in fibrogenesis.氧化还原微小RNA在纤维化形成中的作用。
Redox Biol. 2016 Apr;7:58-67. doi: 10.1016/j.redox.2015.11.006. Epub 2015 Nov 19.
2
Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis.肺纤维化发病机制及临床评估的最新进展。
Eur Respir Rev. 2012 Mar 1;21(123):48-56. doi: 10.1183/09059180.00007611.
本文引用的文献
1
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.特发性肺纤维化：诊断和管理的循证指南（美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会联合发布）
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL.
2
Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011.特发性肺纤维化：诊断和临床管理指南已从2000年基于共识的阶段发展到2011年基于证据的阶段。
Eur Respir J. 2011 Apr;37(4):743-6. doi: 10.1183/09031936.00017711.
3
Pirfenidone for the treatment of Hermansky-Pudlak syndrome pulmonary fibrosis.吡非尼酮治疗 Hermansky-Pudlak 综合征肺纤维化。
Mol Genet Metab. 2011 Jun;103(2):128-34. doi: 10.1016/j.ymgme.2011.02.003. Epub 2011 Mar 21.
4
Morphologic diversity of chronic pigeon breeder's disease: clinical features and survival.慢性鸽饲养者病的形态多样性：临床特征和生存。
Respir Med. 2011 Apr;105(4):608-14. doi: 10.1016/j.rmed.2010.11.026. Epub 2010 Dec 16.
5
Clinical course and prediction of survival in idiopathic pulmonary fibrosis.特发性肺纤维化的临床病程和生存预测。
Am J Respir Crit Care Med. 2011 Feb 15;183(4):431-40. doi: 10.1164/rccm.201006-0894CI. Epub 2010 Oct 8.
6
Non-steroid agents for idiopathic pulmonary fibrosis.用于特发性肺纤维化的非甾体类药物。
Cochrane Database Syst Rev. 2010 Sep 8(9):CD003134. doi: 10.1002/14651858.CD003134.pub2.
7
The multifaceted role of pirfenidone and its novel targets.吡非尼酮的多方面作用及其新靶点。
Fibrogenesis Tissue Repair. 2010 Sep 1;3:16. doi: 10.1186/1755-1536-3-16.
8
Pirfenidone in idiopathic pulmonary fibrosis.吡非尼酮治疗特发性肺纤维化。
Eur Respir J. 2010 Apr;35(4):821-9. doi: 10.1183/09031936.00005209. Epub 2009 Dec 8.
9
Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement.与间质性肺受累相关的胶原血管疾病中的关键临床困境。
Eur Respir J. 2009 Apr;33(4):882-96. doi: 10.1183/09031936.00152607.
10
Pleural plaques and asbestosis: dose- and time-response relationships based on HRCT data.胸膜斑与石棉肺：基于高分辨率CT数据的剂量-反应和时间-反应关系
Eur Respir J. 2009 Jul;34(1):72-9. doi: 10.1183/09031936.00094008. Epub 2009 Jan 7.
Zotero 插件